The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Gilles Salles explains why you should join the virtual Lymphoma Hub Satellite Symposium

Oct 8, 2020

The Lymphoma Hub will hold a virtual satellite symposium at the European Society of Hematology (ESH) 2nd How to Diagnose and Treat: Lymphoma conference, on November 8, 2020, at 3:50 P.M. (CET). The Lymphoma Hub Chair, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, explains why you should join the virtual Lymphoma Hub Satellite Symposium.

Gilles Salles explains why you should join the virtual Lymphoma Hub Satellite Symposium

While frontline treatment approaches in non-Hodgkin lymphomas and CLL have made tremendous progress, the treatment of patients with relapsed/refractory disease can be a challenge. During the Lymphoma Hub satellite symposium , five international experts, Gilles Salles,Marie-José Kersten Kieron Dunleavy Francesc Bosch , and  Astrid Pavlovsky willprovide an overview of the latest advances in the field, special treatment challenges, and regional differencesin approaching treatment decisions for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic lymphoma (CLL).


Your opinion matters

At this year’s virtual ESH Meeting, the Lymphoma Hub Satellite Symposium will evaluate treatment options in patients with R/R DLBCL. What do you think is the most promising emerging therapy in this setting?
4 vote s - 16 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month